Advertisement

Topics

U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

14:30 EDT 13 Jul 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
First and Only Oral Treatment FDA-Approved for Both Non-Metastatic and Metastatic CRPC Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced th...

Other Sources for this Article

Pfizer:
For Media
Jessica Smith, 212-733-6213
jessica.m.smith@pfizer.com
or
For Investors
Ryan Crowe, 212-733-8160
ryan.crowe@pfizer.com
or
Astellas:
For Media
Colin McBean, 847-420-3421
colin.mcbean@astellas.com
or
For Investors
Shin Okubo, 81-3-3244-3202
shin.ohkubo@astellas.com

NEXT ARTICLE

More From BioPortfolio on "U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)"

Advertisement
Quick Search
Advertisement
Advertisement